Low Dose Oral Minoxidil in COVID-19-Associated Telogen Effluvium: A Retrospective Analysis of 69 Patients

    September 2024 in “ Journal of the American Academy of Dermatology ”
    Cesar D. Villarreal-Villareal, Daniela Mares-Custodio, Estefania Boland-Rodríguez, Juan Garza, David Saceda‐Corralo
    Image of study
    TLDR Low-dose oral minoxidil helps hair regrowth in COVID-19-related hair loss with few side effects.
    This retrospective analysis evaluated the effectiveness and safety of low-dose oral minoxidil (LDOM) in treating COVID-19-associated telogen effluvium (CATE) in 69 patients. The study found that LDOM significantly improved hair regrowth in patients suffering from CATE, with minimal adverse effects reported. These findings suggest that LDOM could be a promising treatment option for individuals experiencing hair loss post-COVID-19 infection.
    Discuss this study in the Community →